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Axl-EGFR receptor tyrosine kinase hetero-interaction
provides EGFR with access to pro-invasive signalling in
cancer cells
M Vouri1, DR Croucher2,3,4, SP Kennedy2,5, Q An1, GJ Pilkington1 and S Haﬁzi1
Acquired resistance to conventional and targeted therapies is becoming a major hindrance in cancer management. It is increasingly
clear that cancer cells are able to evolve and rewire canonical signalling pathways to their advantage, thus evading cell death and
promoting cell invasion. The Axl receptor tyrosine kinase (RTK) has been shown to modulate acquired resistance to EGFR-targeted
therapies in both breast and lung cancers. Glioblastoma multiforme (GBM) is a highly inﬁltrative and invasive form of brain tumour
with little response to therapy. Both Axl and EGFR have been identiﬁed as major players in gliomagenesis and invasiveness.
However, the mechanisms underlying a potential signalling crosstalk between EGFR and Axl RTKs are unknown. The purpose of
this study was to investigate this novel and unconventional interaction among RTKs of different families in human GBM cells. With
the use of western blotting, in vitro kinase activity, co-immunoprecipitation and bimolecular ﬂuorescence complementation assays,
we show that EGF stimulates activation of Axl kinase and that there is a hetero-interaction between the two RTKs. Through
small interfering RNA knockdown and quantitative PCR screening, we identiﬁed distinct gene expression patterns in GBM cells that
were speciﬁcally regulated by signalling from EGFR-EGFR, Axl–Axl and EGFR-Axl RTK parings. These included genes that promote
invasion, which were activated only via the EGFR-Axl axis (MMP9), while EGFR-EGFR distinctly regulated the cell cycle and Axl–Axl
regulated invasion. Our ﬁndings provide critical insights into the role of EGFR-Axl hetero-dimerisation in cancer cells and reveal
regulation of cell invasion via Axl as a novel function of EGFR signalling.
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INTRODUCTION
The TAM (Tyro3, Axl and Mer) family of receptor tyrosine kinases
(RTKs) share the structural feature of a two plus two combination
of immunoglobulin-like domains and ﬁbronectin type III repeats in
the extracellular domain, followed by a transmembrane region
and an intracellular tyrosine kinase domain. The natural ligands
for the TAMs are the vitamin K-dependent proteins Gas6
(all three TAMs) and Protein S (Tyro3 and Mer only).1–3 The TAMs
are well-known for a variety of regulatory roles. Axl is the most
well studied TAM receptor to date, to which many cell biological
roles have been attributed, including cell proliferation, survival,
cell adhesion and migration,4 blood clot stabilisation, and
regulation of inﬂammatory cytokines.5,6 Moreover, Axl has been
found to be overexpressed in a variety of cancers.3,7 Even though
Axl does not appear to be an initiator of the oncogenic process,
its overexpression has been correlated with poor prognosis,
promotion of increased invasiveness, epithelial-to-mesenchymal
transition (EMT) and chemoresistance.8,9
One study has shown that Axl overexpression in metastatic
breast cancer is induced by the EMT mediators, Twist, Snail and
Zeb2, in a process in which cells lose their adhesive properties
and increase their migration potential.9 It was shown that Axl
positively impacts on the expression of these mediators, and is
possibly involved in a positive feedback loop.9 In a similar study, it
was shown that Slug and H-Ras-induced EMT in basal-like breast
cancer cells was dependent on the upregulation of the type III
intermediate ﬁlament vimentin, which mediated invasion and
migration in part through upregulating Axl.10 Axl signalling
was also shown to be able to drive migration and extravasation
of breast cancer cells from the bloodstream even in the absence
of vimentin, indicating that Axl is a highly signiﬁcant regulator of
metastasis.10 This is further supported by the fact that Axl has
been shown to regulate migration/invasion through induction of
matrix metalloproteinase 9 (MMP9).11 In addition, Axl activation
stimulated by its ligand Gas6 induced expression of the
pro-survival family of proteins Bcl-2 and Bcl-xL and activated
NF-κB, thus suppressing apoptosis.12 Axl has also been found
to be overexpressed in castration-resistant prostate cancer and to
signiﬁcantly increase migration, invasion and proliferation via
activation of PI3K and NF-κB pathways.13 Recent research also
associated Axl overexpression with poor overall survival of
glioblastoma multiforme (GBM) patients and increased glioma cell
invasiveness.14 We recently showed that inhibition of Axl with a
speciﬁc small molecule inhibitor hinders glioma cell survival,
migration and invasion,15 thus highlighting the viability of
targeting Axl speciﬁcally in cancer therapy.
In addition to its principal oncogenic role, numerous
studies suggest that Axl overexpression mediates secondary
resistance to both conventional and targeted therapies. The most
noteworthy observation to date is acquired resistance to erlotinib
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in EGFR-mutated lung adenocarcinoma by induction of an
EMT-like phenotype through Axl activation.16 Similarly, in another
study, Axl overexpression correlated with acquired resistance to
geﬁtinib.17 Recently, expression of Axl has been identiﬁed as a
predictor of lack of response to the EGFR-targeted inhibitors
lapatinib and erlotinib in triple-negative breast cancer cells.18
Interestingly, it has been found that EGFR signalling transactivates
Axl and that this ligand-independent Axl activity, through possible
hetero-interaction among different RTKs, could then diversify
downstream signalling pathways beyond those triggered by EGFR
alone. Activation of EGFR by EGF stimulation of MDA-MB-231 cells
was shown to lead to both Axl and MET phosphorylation but not
vice versa.18 EGFR-mediated Axl activation led to widespread
downstream signalling changes that were blocked by Axl small
interfering RNA, while Gas6 stimulation had lesser effects. This
pivotal study therefore suggests that Axl can serve as an
ampliﬁer of EGFR signalling.18 Moreover, Axl overexpression lead
to resistance to cetuximab in models of non-small cell lung
cancer and head and neck squamous cell carcinoma.19 Interest-
ingly, in the same study EGFR is shown to positively regulate Axl
expression via the MAPK pathway in a positive feedback loop.19
In the present study, we have identiﬁed for the ﬁrst time a
protein-protein interaction between EGFR and Axl, in which Axl
acts as a gateway for EGFR to access pro-invasive signalling
pathways in GBM cells, which are known for their highly invasive
and proliferative phenotype,20 and which overexpress both
RTKs.14,21 This unconventional hetero-interaction among RTKs
of different classes diversiﬁes the signalling pathways accessible
to both RTKs, and indicates that EGFR-Axl signalling could act as a
master regulator of chemoresistance in several cancers. Thus, it is
of great importance to investigate the cancer phenotypic
repercussions of such a partnership between these RTKs, in
particular with regard to choice and timing of molecular targeted
therapy.
RESULTS
EGF activates Axl in SNB-19 cells via EGFR
In order to investigate the relationship between EGFR and Axl
in GBM cells, we ﬁrst explored Axl activation (through
residue-speciﬁc phosphorylation) in serum-starved SNB-19 cells
in response to stimulation by the growth factors EGF, PDGF and
FGF, over a time course of 0-60 min. EGF, in addition to causing a
rapid increase in EGFR phosphorylation in under 2 min, also
rapidly stimulated Axl phosphorylation within the same time
period (Figure 1a). Interestingly, Axl activation by EGF was possible
only with the fully glycosylated mature 140 kDa Axl but not the
Figure 1. (a) Western blot of time course of EGFR phosphorylation by EGF (50 ng/ml) and of Axl phosphorylation by EGF (50 ng/ml), PDGF
(10 ng/ml) and FGF (10 ng/ml). (b) Western blot of EGFR phosphorylation by EGF and Gas6 and its inhibition by geﬁtinib. (c) Western blot of
Axl phosphorylation by EGF and its inhibition by geﬁtinib and BGB324. (d) Western blot of pERK and pAkt levels after EGF stimulation and
inﬂuence of geﬁtinib and BGB324. Each blot is representative of three separate blots carried out for that experiment.
Axl-EGFR and invasive signalling in cancer cells
M Vouri et al
2
Oncogenesis (2016), 1 – 10
partially glycosylated Gas6 activated 120 kDa form (Figure 1a). The
EGF-stimulated phosphorylation of Axl also occurred in a second
GBM cell line but was not unique to cells of this cancer type, as it
was also observed in cell lines derived from other solid cancers
including breast and head and neck cancer (Supplementary
Figure S1). In contrast, no signiﬁcant change in Axl phosphoryla-
tion occurred after treatment with PDGF or FGF (Figure 1a).
To probe the speciﬁcity of the kinase-substrate relationship,
pre-treatment with the highly selective Axl small molecule
inhibitor BGB32415,22 did not affect the Axl phosphorylation
stimulated by EGF,15 whereas pre-treatment with the EGFR small
molecule inhibitor geﬁtinib blocked Axl phosphorylation following
EGF treatment (Figure 1c). Therefore, Axl activation in response to
EGF is speciﬁc and relies on EGFR activity and not Axl activity,
suggesting a direct phosphorylation of Axl by EGFR. To investigate
whether this cross-phosphorylation observed in SNB-19 cells
occurs in both directions, we tested EGFR phosphorylation
following stimulation by Gas6, the natural ligand for Axl. Gas6
had no effect on EGFR phosphorylation (Figure 1b), indicating a
unidirectional relationship between EGFR and Axl. In addition,
western blotting of pERK and pAkt, two well-known downstream
targets of RTK signalling pathways, showed no change in
phosphorylation upon EGF stimulation in the presence of the
Axl inhibitor BGB324, indicating that the two kinases are regulated
predominantly by EGFR-EGFR or EGFR-Axl signalling in this
context (Figure 1d).
EGFR kinase directly activates Axl kinase in vitro
Having observed that EGF stimulation leads to native Axl
phosphorylation in living cells, we investigated the potential
of EGFR to activate Axl in a cell-free in vitro system. Both
recombinant active Axl and EGFR kinases were able to
phosphorylate the Axl substrate peptide containing Y779, a
residue that is a well-known docking site in Axl for multiple
signalling proteins and a marker of Axl activation23 (Figure 2a).
The in vitro phosphorylation of Axl Y779 by recombinant Axl and
EGFR kinases was also inhibited by their respective small molecule
inhibitors BGB324 and geﬁnitib, whereas BGB324 had no effect on
EGFR kinase activity (Figure 2a).
In addition, we also determined the inﬂuence of EGF-EGFR on
native Axl kinase activity in cells. Axl immunoprecipitated (IPed)
from SNB-19 cells following 5 min incubation with EGF, exhibited a
greater in vitro activity through phosphorylation of the Axl Y779
peptide (Figure 2b). Therefore, Axl is a direct substrate of EGFR
kinase in vitro, as well as in vivo in intact cells following activation
of EGFR by EGF.
Physical association of EGFR and Axl in SNB-19 cells
Next, we investigated whether the observed unidirectional
transactivation of Axl by EGFR occurs through a physical
interaction between the two RTKs. EGFR coIPed with Axl even in
the absence of EGFR stimulation by EGF (Figure 3a), indicating the
existence of an EGFR-Axl complex present at the cell membrane.
Using bimolecular ﬂuorescence complementation imaging, we
observed a constitutive association between Axl and EGFR
proteins at the cell membrane regardless of EGF presence
(Figure 3b). Inhibition of EGFR with geﬁnitib had only slight
effects on the formation of the complex, with a small signiﬁcant
decrease in ﬂuorescence following inhibitor treatment.
Figure 2. (a) In vitro kinase activity of recombinant Axl and EGFR kinases, with Axl Y779 peptide as substrate. Kinases were tested either alone
or in the presence of the speciﬁc Axl or EGFR inhibitors, BGB324 (10μM) and geﬁtinib (10 μM), respectively. Values are normalised against
background Y779 peptide luminescence. (b) In vitro kinase activity of native Axl immunoprecipitated from SNB-19 cells after EGF stimulation,
with or without 1 h geﬁnitib (10 μM) pre-treatment. Data are mean± s.e.m. (n= 3 separate experiments); ****Po0.0001, **Po0.01, *Po0.05
versus untreated.
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EGFR induces upregulation of pro-invasive genes via Axl
Axl has been extensively linked to increased chemoresistance by
activating EMT in a variety of cancers. To investigate any crosstalk
between Axl and EGFR signalling in SNB-19 cells, we treated cells
with EGF with or without concomitant blockade of Axl–Axl
homodimer activation with BGB324, thus directing the effect of
EGF towards the EGFR homodimers or Axl-EGFR heterodimers
only. These treatments were then followed by qRT-PCR analysis of
the expression of 15 EMT-related genes (CD44, CD24, CD133,
ALDH1, CCND1, CDK4, KRT19, NOTCH1, TWIST, MMP9, AKT2, TIMP1,
AKT1, MMP2 and PI3K). Out of these, we observed a signiﬁcant
change in the mRNA levels of CCND1, TIMP1, CD44, MMP2 and
MMP9 genes (Figures 4a-c, respectively). TIMP1 and CD44 mRNA
levels were signiﬁcantly increased (Figure 4a) when Axl
homodimer was blocked during EGF stimulation, whereas CCND1
mRNA was signiﬁcantly increased by EGF stimulation irrespective
of Axl–Axl kinase activity (Figure 4b). Interestingly, EGF stimulation
increased MMP9 mRNA levels, while concomitant Axl inhibition by
Figure 3. Hetero-interaction of EGFR and Axl RTKs. (a) CoIP of Axl and EGFR followed by western blot probing for presence in the complexes of
Axl (left blot) and EGFR (right blot). Control coIP antibody was anti-GAPDH (Ctrl Ig1). (b) Bimolecular ﬂuorescence complementation (BiFC)
images showing EGFR-Axl complex formation followed by ﬂuorescence quantitation bar graph and ﬂuorescence intensity over time following
EGF addition. Data are mean± s.e.m. (n= 3 separate experiments); **Po0.01, *Po0.05 versus untreated.
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BGB324 blocked this, despite presence of EGF (Figure 4c). Also, in
contrast, MMP2 was signiﬁcantly reduced by EGF stimulation only
when Axl signalling was inhibited (Figure 4a).
EGFR positively regulates cell invasion signalling via Axl
We have previously shown Axl signalling to regulate the migration
and invasion of the GBM cells used in this study.15
Therefore, identifying genes involved in invasion to be altered
by EGFR-Axl signalling was of particular interest. In order to
functionally evaluate the importance of this novel interaction,
we treated cells with EGF with or without Axl kinase blockade by
BGB324 or EGFR by geﬁtinib and subsequently observed its
effect on GBM cell invasion (Figure 5b), in the absence
and presence of the speciﬁc RTK inhibitors. EGF stimulation
signiﬁcantly increased cell invasion, an effect that was
counteracted by Axl blockade. Most importantly, combination of
EGFR stimulation with Axl–Axl inhibition led to a greater decrease
Figure 4. EGFR-Axl hetero-interaction regulates the balance between gene expression for invasive and proliferative signalling in SNB-19 cells.
qRT-PCR analysis of (a) TIMP1, MMP2, CD44, (b) CCND1 and (c) MMP9 genes in SNB-19 cells treated for 24 h with 50 ng/ml EGF with or without
2 μM BGB324. Also, qRT-PCR analysis of (d) TIMP1, MMP2, (e) CCND1 and (f) MMP9 genes in SNB-19 cells with small interfering RNA knockdown
of TIMP1 over 3 days, in the presence of EGF (50 ng/ml) with or without Axl blockade by BGB324 (2 μM). Data are mean± s.e.m. (n= 3
independent experiments); ****Po0.0001, ***Po0.001, **Po0.01, * Po0.05.
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in invasion compared to Axl–Axl inhibition alone. More-
over, geﬁtinib was able to reduce cell invasion back
to basal levels. Knockdown of TIMP1 by small interfering RNA
resulted in increased invasion regardless of EGFR–EGFR or
EGFR–Axl stimulation/inhibition, indicating that they act via
TIMP1 to regulate invasion (Figure 5c). In order to further
probe the mechanisms behind this behaviour, we monitored
the mRNA levels of the other altered genes under these
conditions and upon TIMP1 knockdown. We found that
MMP9 mRNA levels were increased upon EGF stimulation, an
effect that was enhanced by TIMP1 knockdown (Figure 4f).
Interestingly, Axl kinase inhibition blocked the EGF-induced
upregulation of MMP9, irrespective of TIMP1 knockdown. In
contrast to MMP9, TIMP1 knockdown had no effect on the
EGF-induced changes in CD44 and MMP2 expression (Figure 4d).
Therefore, these results indicate that Axl positively regulates
cancer cell invasion via the TIMP1-MMP9 axis, also that
EGF activates this pathway only via Axl, and moreover that
discrete EGFR signalling alone in fact directly counteracts Axl
invasive signalling.
EGFR stimulates cell cycle progression independent of Axl
We further investigated the observed increase in the CCND1 gene,
which codes for cyclin D1, on the cell cycle in SNB-19 cells. Cell
cycle analysis after treatment with EGF alone or in combination
with BGB324 revealed a decrease of cells in the G1 phase with a
concomitant increase in the G2/M population, irrespective of
Axl–Axl kinase activity (Figure 5a). This reﬂected the observed
EGF-induced increase in CCND1 mRNA expression (Figure 4b),
occurring irrespective of TIMP1 expression (Figure 4e) as a
conﬁrmation of its separation from invasion signalling. Therefore,
EGFR-EGFR signalling alone stimulates cell cycle progression in
SNB-19 cells in addition to attenuating Axl invasive signalling.
DISCUSSION
In this study, we have identiﬁed for the ﬁrst time a direct
interaction between EGFR and Axl RTKs, with EGF/EGFR-induced
activation of Axl as a novel signalling pathway to invasion in
cancer cells. Our results here show that Axl heterodimerises
with EGFR, as shown by co-IP and bimolecular ﬂuorescence
Figure 5. (a) Cell cycle analysis of cells treated for 24 h with EGF alone or EGF in combination with BGB324. (b) Invasion assay for SNB-19 cells
following treatment with EGF, BGB324 and geﬁnitib using PDGF-AA as chemoattractant. (c) Invasion assay for SNB-19 cells with small
interfering RNA knockdown of TIMP1 over 3 days, in the presence of EGF (50 ng/ml). Data are mean± s.e.m. (n= 3 independent experiments);
****Po0.0001, ***Po0.001, **Po0.01, *Po0.05 compared to either untreated/controls or as indicated. # indicates signiﬁcance when
compared with EGF treatment.
Axl-EGFR and invasive signalling in cancer cells
M Vouri et al
6
Oncogenesis (2016), 1 – 10
complementation imaging, which adds diversiﬁcation to
downstream signalling and subsequently cell behaviour. EGF,
and not the other growth factors PDGF and FGF, stimulated
activation of Axl directly through EGFR–Axl hetero-interaction. This
occurred in a unidirectional manner, i.e. that EGFR activated Axl
but not vice versa. The activation of Axl was shown to occur
through direct phosphorylation by EGFR of Axl tyrosine 779,
one of the key residues within Axl that serves as a multi-substrate
docking site for further downstream signalling.23 The directionality
of the relationship between EGFR and Axl was evident from use of
speciﬁc inhibitors of the two RTKs. BGB324 inhibited intrinsic
Axl kinase activity and therefore Axl–Axl, as has previously
been reported by ourselves15 and others. However, BGB324
did not prevent EGFR from phosphorylating Axl and thereby
creating docking sites in Axl (such as pY779) for intracellular
signalling mediators; this scenario involves EGFR–Axl hetero-
association. Therefore, a distinction is apparent between Axl–Axl
signalling and EGFR–Axl signalling, in which Axl is the passive
partner as a kinase.
In addition, EGFR stimulated activation of native Axl protein in
SNB-19 cells, an effect that was reduced by speciﬁc inhibition of
EGFR. However, it is possible that some of the Y779 phosphoryla-
tion measured in this kinase assay could be due to EGFR pulled
down along with Axl, thus the kinase activity exhibited in vitro
could be due to both RTKs. Nevertheless, our combined
experiments show that EGFR enhances Axl activity, and in
agreement with our ﬁndings, Meyer and colleagues have shown
that EGF stimulation transactivated Axl in breast cancer cells
(which we also observed here), which intensiﬁed downstream
EGFR signalling.18 Tyrosine 779 of Axl is a major kinase target
and docking site for several intracellular signalling adaptors
and kinases.1,23 Therefore, Axl phosphorylation by EGFR on
key residues such as this would be expected to form new
protein docking sites and subsequent activation of alternative
downstream signalling pathways which would otherwise not
be canonically regulated by either receptor alone through
homo-dimerisation. Recently, Elkabets et al. showed that Axl
activates the EGFR/PKC/mTOR axis in head and neck and
oesophageal squamous cell carcinomas in order to arbitrate
resistance to PI3Kα inhibitors.24 However, here we did not observe
any effect on EGFR phosphorylation by Gas6-induced Axl
activation (which we have previously shown in this cell line15).
Furthermore, speciﬁc Axl kinase small molecule inhibition did not
hinder its phosphorylation by EGFR,15 indicating that the event
occurs independently of Axl kinase. The speciﬁcity of BGB324 at
these concentrations for Axl versus Tyro3 and EGFR RTKs has been
shown in previous work from our lab.15
We identiﬁed MMP9 gene to be speciﬁcally regulated by
Axl–EGFR signalling but neither RTK alone. Furthermore, the MMP2
gene as well as the anti-invasive gene TIMP1 seem to be
exclusively regulated by Axl–Axl signalling as EGF stimulation
had no effect on their expression, but Axl blockade resulted in a
signiﬁcant increase in TIMP1 levels whereas MMP2 levels where
signiﬁcantly reduced. On the other hand, the CCND1 gene appears
to be exclusively regulated by EGFR–EGFR signalling irrespective
of Axl kinase activity; EGF stimulation signiﬁcantly upregulated
CCDN1, which was not altered by Axl kinase blockade.
In order to further investigate the effect of TIMP1 signalling on
cell behaviour, we performed cell invasion assays where we
transiently knocked down TIMP1 and stimulated with EGF. As
expected, TIMP1 knockdown on its own resulted in a signiﬁcant
increase in cell invasion, while EGF stimulation signiﬁcantly
added to the TIMP1 knockdown effect. This observation indicates
a pro-invasive signalling outcome for the EGFR-Axl hetero-
interaction, which is normally counteracted by EGFR stimulation
of TIMP1 expression. Moreover, EGF stimulation led to a signiﬁcant
increase in invasion, an effect that was counteracted by Axl–Axl
kinase inhibition. However, EGFR activation in combination with
Axl kinase inhibition signiﬁcantly reduced baseline cell invasion to
a greater extent than Axl inhibition alone. Indeed, an increase in
TIMP1 mRNA was observed upon EGF stimulation in concert
with Axl inhibition, which can account for this phenomenon.
Furthermore, EGFR inhibition alone was able to restore the
number of invaded cells back to baseline indicating that EGFR
alone cannot account for the invasive potential of these cells.
With the purpose of identifying why EGFR activation further
increased cell invasion under these conditions, we also investi-
gated and conﬁrmed increases in MMP2 and MMP9 genes.
Interestingly, previous studies have established MMP9 to be
directly regulated by Axl in breast cancer11 and MMP2 in ovarian
cancer25 independently of TIMP1 activity. Given our results, we
found that in GBM cells, the EGFR-Axl axis promotes invasion
through upregulation of MMP9, while Axl regulates MMP2
expression independently of EGFR or TIMP1. Our results are
supported by previous studies that reported that MMP9 binds to
TIMP1 while failing to bind MMP2.26 Furthermore, Axl has been
reported to regulate MMP2 at the transcriptional level in ovarian
cancer through the PI3K pathway.25 We have previously shown Axl
to activate the PI3K pathway in glioma and Axl inhibition to
suppress it,15 indicating that the same regulation exists in glioma.
In addition, the gene for cyclin D1, CCND1, was upregulated
upon EGF stimulation, irrespective of Axl kinase activity. Coupled
with this, cell cycle analysis revealed that EGF stimulation, with or
without Axl blockade, drove cells to enter mitosis. Therefore,
these data show that EGF/EGFR-EGFR signalling promotes cell
proliferation through upregulation of TIMP1 and cyclin D1,27 while
EGFR can also exploit Axl signalling to promote cell invasion
through downregulation of TIMP1 and CCND1 with concomitant
MMP9 upregulation.
Axl has previously been shown to mediate resistance to EGFR
inhibitors by promoting EMT in breast18 and lung16 cancers.
Therefore, based on this and our observations, it appears that
EGFR and Axl can co-exist in local clusters on the plasma
membrane, leading to subsequent activation-dependent
enhancement of interactions after ligand stimulation. Therefore,
it follows that drugs disrupting this complex interaction may be
efﬁcacious in counteracting such signal diversiﬁcation and thereby
more effective in combating both primary and secondary
resistance in tumours with the appropriate molecular targets.18
In conclusion, we have shown a speciﬁc relationship between
EGFR and Axl RTKs, enabled through a direct protein-protein
interaction, which diversiﬁes the signalling pathways available to
EGFR. Having previously shown that Axl signalling is required for
GBM cell invasion,15 we now show here for the ﬁrst time that EGFR
can also signal via Axl to promote cell invasion (Figure 6), a role for
which EGFR, being a major mitogenic growth factor, is not
well-known as a single entity. Furthermore, it is likely that
EGFR-Axl signalling balances invasion and proliferation through
the regulation of key genes such as CCND1, TIMP1 and CD44;
indeed, EGFR alone promotes expression of these genes while
EGFR-Axl supresses their expression. Given these observations, it is
conceivable that a combination of EGFR and Axl inhibition can be
more effective than monotherapy for treating some cancer
patients, in particular as a means to prevent or delay secondary
resistance to targeted therapy.
MATERIALS AND METHODS
Cell lines and reagents
The immortalised human GBM cell line SNB-19 (DSMZ German cell culture
bank) was authenticated and veriﬁed free of mycoplasma through
in-house testing as previously described.28 Cells were cultured in
Dulbecco’s Modiﬁed Eagle Medium (Thermo Fisher Scientiﬁc, Loughbor-
ough, UK) supplemented with 10% foetal bovine serum (Lonza, Slough,
UK), 1% L-glutamine (Life technologies, Paisley, UK) and 1% penicillin/
streptomycin (Thermo Fisher Scientiﬁc). Cells were routinely grown in a
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humidiﬁed incubator with 5% CO2 at 37 °C, and subcultured through
dissociation with trypsin/EDTA (Lonza) and proportional reseeding. Cells
were always grown to near conﬂuence (90%) before experimental use.
Cell treatments
SNB-19 cells were serum starved for 24 h before being treated at indicated
times with recombinant human proteins, including Gas6 (400 ng/ml),
epidermal growth factor (EGF; 50 ng/ml), platelet-derived growth factor
(PDGF; 10 ng/ml) or ﬁbroblast growth factor (FGF; 10 ng/ml; Bio-techne,
Abingdon, UK). In inhibition experiments, the EGFR small molecule
inhibitor geﬁtinib (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or the
Axl small molecule inhibitor BGB324 (BerGenBio AS, Bergen, Norway) were
pre-incubated with cells for 1 h prior to EGF stimulation.
Western blotting
Cell extracts were separated by SDS-PAGE and proteins identiﬁed by
western blotting, as previously described.15 Antibodies used for western
blot detection were as follows: Axl (C-20), pEGFR, Akt 1/2/3 and pAkt 1/2/3
(Santa Cruz), EGFR (Cell Signalling Technology, Leiden, The Netherlands)
and pAxl 779 (Bio-techne). Secondary antibodies used were horseradish
peroxidase (HRP)-conjugated anti-rabbit (Dako, Cambridge, UK), anti-goat
and anti-mouse Igs (Promega, Southampton, UK).
Immunoprecipitation
SNB-19 cells were grown to conﬂuency and treated with EGF (50 ng/ml) for
5 min prior to lysis. To extract proteins, cells were washed with ice-cold
PBS and lysed in IP lysis buffer (Thermo Fisher). Following a 10 min
centrifugation at 10 000 g, the lysates were pre-cleared by incubation with
10 μl protein A/G-agarose beads (Santa Cruz) for 1 h at 4 °C with constant
rotation. Lysates were then incubated with 2 μg Axl or EGFR IP antibodies
for 2 h at room temperature, with constant rotation. Antibodies against
GAPDH or Tensin2 (Santa Cruz) were used as species-aligned negative
control IP antibodies. Following incubation, 20 μl of protein A/G-agarose
beads was added to each sample and incubated further for 2 h. The beads
were then separated by centrifugation at 8000 g for 1 min and washed
once with ice-cold IP lysis buffer and thrice with PBS (Thermo Fisher
Scientiﬁc). Finally, 4 × SDS-PAGE loading buffer was added to the beads
and solubilised samples underwent SDS-PAGE and western blotting.
In vitro kinase activity assay
The Axl Kinase Enzyme System (Promega) was employed according to the
manufacturer’s protocol with minor modiﬁcations. Brieﬂy, each of
recombinant Axl or EGFR kinases (Stratech Scientiﬁc, Suffolk, UK) were
incubated for 30 min with the substrate peptide (DCLDGLYALMSRC,
0.2 μg/μl; Pepceuticals Ltd., Leicester, UK) that contained tyrosine 779
(Y779) of human Axl within it, in the presence or absence of the EGFR
inhibitor geﬁtinib (10 μM) or Axl inhibitor BGB324 (10 μM), in Kinase assay
reaction buffer containing ATP (25 μM). DMSO was used as vehicle control
instead of inhibitor. ADP-Glo reagent was then added to the wells and
incubated at room temperature for 60 min followed by addition of Kinase
detection reagent, with further incubation for 30 min at room temperature.
Luminescence was read using a microplate luminometer (BMG Labtech
Fluorstar Optima, Offenburg, Germany).
To determine the kinase activity of native Axl pulled down from SNB-19
cells by IP, the pellet of protein A/G-agarose beads obtained from Axl IP
(described above) was washed a ﬁnal time with Axl reaction buffer
(8000× g for 1 min). The Kinase assay reaction buffer, containing ATP
(25 μM) and the Axl substrate peptide (0.2 μg/μl) (Promega) were added
directly to the pellet, and the kinase reaction incubated for 30 min at room
temperature. The reaction was stopped, developed and detected in the
same way as for recombinant kinases above.
Bimolecular ﬂuorescence complementation
Bimolecular ﬂuorescence complementation vectors were generated by
gateway cloning with donor vectors containing Axl (pDONR223-Axl,
Addgene plasmid 23945) or EGFR (pDONR223-EGFR, Addgene plasmid
23935).29 These were cloned into pDEST-ORF-V1 (Addgene plasmid 73637)
and pDEST-ORF-V2 (Addgene plasmid 73638), respectively. An expression
vector encoding full length Venus ﬂuorescent protein was also utilised as
control. For confocal microscopy, HEK-293T cells expressing an
H2B-mCherry nuclear marker were grown on glass coverslips within a
six-well plate. These were transfected with 500 ng of each vector (or Venus
control) using Polyplus Jetprime and incubated for 16 h. The
coverslips were prepared for confocal microscopy by ﬁxation with 1%
Figure 6. Schematic summary of the results of this study, showing Axl homo-dimerisation to inhibit TIMP1 expression and promote MMP2
expression (left panel), while EGFR homodimers promote CCND1 expression (middle panel), and EGFR-Axl hetero-interaction, with
unidirectional activation of Axl by EGFR, leads to activation of pro-invasive signalling pathways, involving MMP9 as a central regulator
(right panel).
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paraformaldehyde for 5 min at room temperature. For high-content
analysis, HEK-293T cells expressing an H2B-mCherry nuclear marker were
grown on Greiner CELLSTAR 96-well plates in phenol red free media
(Thermo Fisher Scientiﬁc). Each well was transfected with 20 ng of each
vector (or Venus control) using Polyplus Jetprime and incubated for 16 h,
in the presence of absence of geﬁtinib at the concentrations indicated.
Single cell ﬂuorescence intensity was measured using the ArrayScan XTI
Live High Content Platform (Thermo Fisher Scientiﬁc).
Cell invasion assay
Invasion of SNB-19 cells through extracellular matrix was measured using a
modiﬁed insert chamber coated with matrix proteins in 24-well culture
plates, using PDGF-AA as chemoattractant, as previously described.15
Brieﬂy, cells were treated with EGF (50 ng/ml), BGB324 (5 μM) and/or
geﬁtinib (5 μM) for 16 h and allowed to invade through the pore-containing
membrane over 16 h after which they were ﬁxed with paraformaldehyde
(Sigma, Poole, UK) and stained with 0.5% crystal violet (Fisher,
Loughborough, UK) for 30 min. Invaded cells were counted in 5 separate
ﬁelds. In some experiments, prior to the assay, cells were transfected with
10 nM TIMP1 or Control small interfering RNA (Santa Cruz) for 72 h, and/or
treated with EGF (50 ng/ml) or BGB324 (2 μM) for 16 h.
Quantitative reverse transcription polymerase chain reaction
Cellular total RNA was isolated using GeneJET RNA puriﬁcation kit
(Life Technologies) according to the manufacturer’s protocol. First-strand
cDNA was synthesised using a reverse transcription kit (nanoScript;
PrimerDesign, Southampton, UK). Quantitative PCR (qPCR) ampliﬁcation
was performed in 96-well plates in a qPCR mastermix using either SYBR
Green or ﬂuorescent probes (Roche, Burgess Hill, UK) and run on a
LightCycler 96 System (Roche). For the human EMT gene expression
screen, the qPCR ampliﬁcations were performed using the Human CSC and
EMT Biomarker RT Array Kit (NanoCinna Technologists Ltd., Tehran, Iran).
Further qPCR investigations of individual genes were performed using
pre-designed primers/probes for TIMP1 (NM_003254), MMP2 (NM_004530),
CCND1 (NM_053056), CD44 (NM_001001389) (Integrated DNA
Technologies; Leuven, Belgium). Relative expression analysis was
performed using the equation N=N0× 2
Cp (LightCycler 96 software;
Roche), normalising against the gene for ATP synthase subunit beta
(ATP5B) (Life Technologies).
Cell cycle analysis
SNB-19 cells were serum starved for 24 h prior to being treated with
50 ng/ml EGF alone or in combination with 2.5 μM BGB324, or vehicle
(DMSO) for 24 h. Following drug treatments, the cells were centrifuged at
400 g for 5 min, washed with PBS and resuspended in 70% ethanol/PBS
(Thermo Fisher Scientiﬁc) for 2 h on ice. Following a PBS wash, the cells
were incubated with 1 μg/ml DAPI, 0.1% Triton X-100 in PBS (Chemometec
A/S, Allerød, Denmark) for 5 min at 37 °C. Thirty μl of stained cells
was loaded onto a special chamber slide (NC-Slide A2) and cell
populations were analysed for DAPI ﬂuorescence (NucleoCounter NC-3000;
Chemometec) according to the manufacturer’s protocol.
Statistical analyses
All data are expressed as mean± s.e.m., obtained from a minimum of 3
independent experiments, each constituting multiple replicates per
condition as speciﬁed in the ﬁgure legends. Quantitative data were
analysed by Analysis of Variance (ANOVA) with post hoc Tukey test
for multiple comparisons with one control group or multiple time
points per treatment, or paired t-test for pairwise comparisons of
control with treatment. Statistical analyses of data and their graphical
representations were performed using Prism software (GraphPad Software
Inc, San Diego, CA, USA). The level of statistical signiﬁcance is indicated in
the ﬁgures and accompanying legends, with Po0.05 considered as
statistically signiﬁcant. Western blot image processing was performed
using Adobe Photoshop CC 2014 software (Adobe Systems Incorporated,
San Jose, CA, USA).
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